Cardiovascular / Vasoactive Research Peptides Guide

This guide covers 6 research peptides in the Cardiovascular / Vasoactive category. Each compound is evaluated on its evidence base, mechanism, safety profile, and current clinical status.

Angiotensin II is an endogenous octapeptide (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, MW ~1046.2 g/mol) that plays a pivotal role in the renin-angiotensin-aldosterone system (RAAS), primarily functioning as a vasopressor. It is uniquely established as the only exogenous angiotensin II product, FDA-approved under the brand name Giapreza since December 2017, specifically for the treatment of vasodilatory shock in adults. Research indicates that Angiotensin II can effectively raise blood pressure in critically ill patients, particularly those experiencing septic shock. In clinical settings, it has demonstrated significant efficacy, although its use is primarily limited to critical care environments. Limitations include potential adverse effects such as increased cardiovascular workload and the need for careful monitoring during administration.

Angiotensin 1-7, a heptapeptide (Asp-Arg-Val-Tyr-Ile-His-Pro, MW ~899.0 g/mol), emerges from the cleavage of angiotensin II by ACE2 and acts as a counter-regulatory component of the renin-angiotensin system. This peptide has garnered attention for its potential cardiovascular protective effects, opposing the vasoconstrictive actions of angiotensin II and exhibiting anti-inflammatory properties. Despite its promising mechanisms, Angiotensin 1-7 remains in the realm of preclinical and early-phase research, with no therapeutic indications currently approved. Studies suggest its potential role in mitigating conditions such as hypertension and heart failure, but further investigation is necessary to establish clinical applicability and safety profiles.

Bradykinin, a nonapeptide (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg, MW ~1060.2 g/mol), is a well-characterized endogenous mediator produced through the kallikrein-kinin system. It is recognized for its potent vasodilatory effects, as well as its involvement in pain signaling and inflammatory responses. While bradykinin itself is not used therapeutically as an exogenous drug, it plays a crucial role in understanding the side effects associated with ACE inhibitors, notably cough and angioedema. Research has highlighted its significance in various pathological conditions, including hereditary angioedema, where dysregulation of bradykinin levels leads to acute episodes. The absence of approved therapeutic applications for bradykinin emphasizes the need for continued exploration of its mechanisms and potential utility in clinical settings.

Endothelin-1 (ET-1), a 21-amino-acid peptide (MW ~2491.9 g/mol), is primarily secreted by endothelial cells and is recognized as the most potent endogenous vasoconstrictor. Its prolonged effects on vascular tone have made it a focal point in cardiovascular research, particularly concerning pulmonary arterial hypertension (PAH). Although ET-1 itself is not used therapeutically, endothelin receptor antagonists such as bosentan, ambrisentan, and macitentan have received FDA approval for the treatment of PAH, demonstrating the clinical relevance of targeting the endothelin pathway. Research continues to elucidate the complex role of ET-1 in various cardiovascular diseases, with an emphasis on understanding its mechanisms and potential implications for therapy.

Apelin, an endogenous peptide derived from the preproapelin precursor, exists in several bioactive forms including apelin-13, apelin-17, and apelin-36. This peptide is known to interact with the APJ receptor (APLNR), influencing cardiovascular functions such as blood pressure regulation, fluid homeostasis, and cardiac contractility. Despite its emerging significance in cardiovascular research, Apelin remains in preclinical and early-phase clinical investigations, with no approved therapeutic indications to date. Studies suggest a potential role in conditions like heart failure and obesity-related cardiovascular complications, yet further research is warranted to clarify its therapeutic potential and safety profile in clinical applications.

Adrenomedullin is a 52-amino-acid peptide with a molecular weight of approximately 6028 g/mol, initially discovered in human pheochromocytoma tissue. This peptide is significantly expressed across various tissues, including the cardiovascular system, lungs, kidneys, and adrenal glands, where it exerts vasodilatory, natriuretic, and cardioprotective effects. Current research focuses on the use of its precursor, MR-proADM, as a prognostic biomarker for conditions such as sepsis and heart failure. Studies indicate that elevated levels of MR-proADM correlate with adverse outcomes in patients, suggesting its utility in risk stratification. However, it is crucial to note that while MR-proADM is gaining traction in clinical settings, there is currently no approved therapeutic application for adrenomedullin itself. The ongoing exploration of adrenomedullin in cardiovascular research underscores its potential importance, yet the absence of therapeutic approval highlights the need for further studies to validate its efficacy and safety in clinical practice.